KWILP
APLS

Kiwi Wealth Investments Limited Partnership’s Apellis Pharmaceuticals APLS Stock Holding History

Kiwi Wealth Investments Limited Partnership’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23,201
Closed -$1.47M – 235
2021
Q2 		$1.47M Buy
+23,201
New +$1.2M 0.08% 181

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Kiwi Wealth Investments Limited Partnership's APLS Position: Q3 2021 in Review

Kiwi Wealth Investments Limited Partnership sold out of Apellis Pharmaceuticals (APLS) in Q3 2021, closing a stake of 23,201 shares — an estimated $1.47M sold.

Kiwi Wealth Investments Limited Partnership first reported a position in APLS in Q2 2021 and held it in 1 quarter. The position peaked at $1.47M in Q2 2021. 181 funds tracked by Wall St. Rank hold APLS as of Q3 2021.

  • Kiwi Wealth Investments Limited Partnership reported no remaining Apellis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Kiwi Wealth Investments Limited Partnership sold 23,201 Apellis Pharmaceuticals shares in Q3 2021, an estimated $1.47M.
  • Kiwi Wealth Investments Limited Partnership first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Kiwi Wealth Investments Limited Partnership's Apellis Pharmaceuticals position peaked at $1.47M in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2021.

Based on Kiwi Wealth Investments Limited Partnership's 13F filing for Q3 2021, filed 16 Nov 2021.